Wynik wyszukiwania w bazie Polska Bibliografia Lekarska GBL

Zapytanie: RUBIO
Liczba odnalezionych rekordów: 2

Przejście do opcji zmiany formatu | Wyświetlenie wyników w wersji do druku


Tytuł oryginału: Imunocytochemical evidence for growth hormone-releasing hormone in the tanycytes of the median eminence of the rat.
Autorzy: Carretero Jos‚, Burks Deborah, Rubio Manuel, Blanco Enrique, Herrero Julio J., Bodego Pilar, Juanes Juan A., Hernandez Elena, Riesco Jos‚ M.
Źródło: Folia Morphol. 2002: 61 (4) s.209-216, il., tab., bibliogr. 69 poz.
Sygnatura GBL: 301,720

Hasła klasyfikacyjne GBL:
  • endokrynologia
  • neurologia

    Typ dokumentu:
  • praca doświadczalna
  • tytuł obcojęzyczny

    Wskaźnik treści:
  • zwierzęta
  • szczury
  • płeć męska
  • płeć żeńska

    Streszczenie angielskie: The current study was performed to analyse the potential existence and structure of a GHRH-transporting tuberoinfundibular system in the rat median eminence. The immunocytochemical analysis using anti-GHRH revealed an intense immunoreaction in the ependimary cells, tanycytes, at the level of the floor of the infundibular recess forming part of the median eminence. The basal processes of these cells course towards the external layer of the median eminence and reach the growth hormone-releasing hormone (GHRH) fibres of the tuberoinfundibular tract and this reaction was incrase after intraventricular treatment with colchicine. Thus, these observations suggest the existence of a second ora alternative cerebrospinal fluid-mediated route of GHRH transport to the median eminence and implicate the involvement of tanycytes in the regulation of this novel transport system.


    Tytuł oryginału: Resistance mutations in HIV-infected patietns experiencing early failure with nelfinavir-containing triple combinations.
    Autorzy: Nuńez Marina, Mendozaut. Carmen de, Valer Luisa, Casas Esperanza, López-Calvo Soledad, Castro Angeles, Rosón Beatriz, Podzamczer Daniel, Rubio Amalia, Berenguer Juan, Soriano Vincent
    Źródło: Med. Sci. Monitor 2002: 8 (9) s.CR620-CR623, tab., bibliogr. 20 poz.
    Sygnatura GBL: 313,278

    Hasła klasyfikacyjne GBL:
  • toksykologia
  • aIDS
  • genetyka

    Typ dokumentu:
  • tytuł obcojęzyczny
  • praca kliniczna

    Wskaźnik treści:
  • ludzie
  • dorośli 19-44 r.ż.
  • dorośli 45-64 r.ż.

    Streszczenie angielskie: Background: The purpose of our study was to assess the presence of nelfinavir (NFV)-associated resistance mutations at the time of early virological failure in subjects receiving NFV as part of a first protease inhibitor (PI)-based triple regimen. Material/Methods: Subjects failing their first PI-based NFV-containing triple regimen were identified in six Spanish hospitals. HIV genotyping was carried out in plasma samples collected at the time of the first viral rebound. Results: Upon initiation of NFV-based therapy, 19 of the 30 subjects (63 p.c.) werena‹ve; 11 (37 p.c.) had been exposed to nucleoside analogues. Median HIV-RNA at the time of viral rebound was 4, 180 copies/ml. PCR-amplified products were obtained in 22 subjects (73 p.c.). These products were sequenced and primary PI resistance mutations were recognized in 6 patietns (27 p.c.). All six individuals harbored the D30N mutation, and none presented the L90M mutation. Other PI resistance mutations were present in 5 subjects (at codons 36, 63, 71, 77, 82 and/or 88). Secondary PI resistance mutations were present in another 9 subjects. By contrast, mutations conferring resistance to reverse transcriptase nhibitiors were present in 50 p.c. of the patietns, and the M184V substitution was the most frequently seen. Conclusions: Nearly 75 p.c. of patietns failing their first PI-based triple regiment containing NFV do not harbor PI resistance mutations. THe D30N substitution, rather than L90M, is the msot frequently recognized, which does not challenge the efficacy of further rescue interventions with other PIs. This observation supports the use of nelfinavir as first protease inhibitor.

    stosując format: